Obstetrics/Gynecology
RSSArticles
-
Despite new options, oral contraceptive pills are still in birth control mix, survey respondents say
How are oral contraceptives being used in today’s family planning practices? The Affordable Care Act (ACA) might be making a difference when it comes to use of the Pill. Between 2012 and 2013, the number of women who filled prescriptions for the Pill with no co-pay more than quadrupled from 1.2 million to 5.1 million, according to data from the IMS Institute for Healthcare Informatics in Parsippany, NJ, an information and technology service.
-
Oral contraceptives — Should they be OTC?
When it comes to moving oral contraceptives over the counter (OTC), almost 50% of participants in the Contraceptive Technology Update Contraception Survey say they support such a move. Support for OTC access is growing; 62% of American women support the pill being available without a prescription.
-
With unsurpassed efficacy and rapid reversibility, contraceptive implant can be put into practice
While use of long-acting reversible contraceptive (LARC) methods is growing, the contraceptive implant (Nexplanon, Merck & Co., Whitehouse Station, NJ) is still underused, say family planning experts. Look at the most recent national figures: In 2009, 8.5% of women using contraceptives relied on LARC methods, rising from 5.5% in 2007 and 2.4% in 2002. However, most of these women (nearly 8%) use intrauterine devices (IUDs), compared to less than 1% who use the implant.
-
Ortho Evra patch discontinued — What next?
Rewind to 2002: The first transdermal contraceptive, the Ortho Evra patch, hit U.S. pharmacy shelves. Fast forward to the present: The manufacturer has production of the device “due to a business decision,” according to information on the Food and Drug Administration (FDA) website.
-
CTU remembers Michael Rosenberg, MD, MPH
The reproductive health research community is paying tribute to Michael Rosenberg, MD, MPH, founder and chief executive officer of the Durham, NC-based clinical research organization, Health Decisions. Rosenberg was killed in a Dec. 8 plane crash in Maryland.
-
For Methods that are Reversible and Long-acting, the Upswing Continues
Our annual contraception survey shows “dramatically more” women choosing intrauterine and implant contraception.
-
Use of Cervical Length and Fetal Fibronectin in Preterm Labor
SYNOPSIS: A large 10-center study has validated the concept of screening all patients who are presenting with preterm contractions in the third trimester with cervical length examinations by transvaginal sonography and using fetal fibronectin selectively only in those with cervical lengths between 1.5 and 3.0 cm.
-
Empagliflozin Tablets (Jardiance ®)
A new sodium glucose co-transporter 2 (SGLT2) has been approved by the FDA. Empagliflozin follows canagliflozin (Invokana) and dapagliflozin (Farxiga)as the third entry in this group. These drugs reduce plasma glucose levels by reducing renal absorption of filtered glucose. Empagliflozin is marketed by Boehringer Ingelheim as Jardiance. -
Good Ol’ Vitamin C: Does It Deserve Another Look for Your Heart?
SYNOPSIS: A meta-analysis and systematic review found vitamin C supplementation improved endothelial function in patients with diabetes, atherosclerosis, and heart failure. -
Stopping Colonoscopy at Age 75 ¡ª Even With a History of Colon Cancer
SYNOPSIS: The incidence of colorectal cancer is much less in people > 75 years of age compared with ages 50-74, even in patients with a personal history of colon cancer or adenomatous polyps. Complication rates for colonoscopy are high in the elderly ¡Ý age 75 and in patients with comorbidities. Surveillance colonoscopy may be stopped in the advanced elderly and in comorbid elderly patients.